New hope for advanced breast cancer: drug combo targets resistant tumors

NCT ID NCT06764186

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study tests a combination of two drugs, capivasertib and fulvestrant, in people with a certain type of advanced breast cancer (HR+/HER2-) that has stopped responding to standard hormone therapy and a CDK4/6 inhibitor. The goal is to see how well the combo works in real-world settings in Spain. About 101 participants with specific genetic changes (PIK3CA/AKT1/PTEN) will be followed to measure how long until they need another cancer treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Alicante, 03010, Spain

  • Research Site

    Barcelona, 08003, Spain

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Bilbao (Vizcaya), 48013, Spain

  • Research Site

    Córdoba, 14004, Spain

  • Research Site

    Donostia / San Sebastian, 20014, Spain

  • Research Site

    El Palmar, 30120, Spain

  • Research Site

    Girona, 17007, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Oviedo, 33011, Spain

  • Research Site

    Palma deMallorca, 07010, Spain

  • Research Site

    Salamanca, 37007, Spain

  • Research Site

    Santander, 39008, Spain

  • Research Site

    Seville, 41073, Spain

  • Research Site

    Valencia, 46026, Spain

  • Research Site

    Zaragoza, 50009, Spain

Conditions

Explore the condition pages connected to this study.